ANALYSIS OF P53 AND RAS GENE-MUTATIONS IN HEPATOCELLULAR-CARCINOMA IN ITALY

被引:2
作者
CONTE, D
NERI, A
FRACCHIOLLA, NS
CROCE, LS
LODI, L
FRAQUELLI, M
MASUTTI, F
TIRIBELLI, C
机构
[1] Department of Gastroenterology, Institute of Medical Science, University of Milan, IRCCS Ospedale Maggiore, Milan
[2] Laboratory of Haematology and Molecular Genetics, University of Milan, IRCCS Ospedale Maggiore, Milan
[3] Liver Research Centre, Trieste
关键词
P53 TUMOR SUPPRESSOR GENE; H-RAS AND K-RAS ONCOGENES; CIRRHOSIS; HEPATOCELLULAR CARCINOMA;
D O I
10.1097/00042737-199411000-00006
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective: To evaluate the frequency of p53 tumour suppressor gene and H- and K-ras oncogene mutations in both neoplastic and distant cirrhotic non-neoplastic tissue in Italian patients with hepatocellular carcinoma (HCC). Patients: Ten men and four women (mean age 62 +/- 7 years) with HCC associated with cirrhosis, who underwent resection. More than half the patients had a lesion over 3 cm in diameter and in 12 cases carcinoma was well differentiated. Methods: Exons 4 to 9 of p53 and codons 12, 13 and 61 of the H- and K-ras genes were analyzed by the polymerase chain reaction-single strand conformation polymorphism method in both neoplastic and non-adjacent cirrhotic tissue and in cell lines harbouring known mutations as positive controls. Results: No aberrant migrating fragments were observed in tumoral and cirrhotic non-neoplastic tissue. Conclusions: Our findings suggest that p53 mutation is a rare occurrence in HCC, at least in countries with a low incidence of this cancer. They also confirm that H- and K-ras mutations are infrequent in HCC and play a minimal role in hepatocarcinogenesis.
引用
收藏
页码:1005 / 1008
页数:4
相关论文
共 35 条
[1]  
Harris C.C., Hollstein M., Clinical implications of the p53 tumour-suppressor gene, N Engl J Med, 329, pp. 1318-1327, (1993)
[2]  
Hollstein M., Sidransky D., Vogelstein B., Harris C.C., P53 mutations in human cancers, Science, 253, pp. 49-53, (1991)
[3]  
Bos J.L., Ras oncogenes in human cancer: A review, Cancer Res, 49, pp. 4682-4689, (1989)
[4]  
Levine A.J., Momand J., Finlay C.A., The p53 tumour suppressor gene, Nature, 351, pp. 453-456, (1991)
[5]  
Vogelstein B., Kinzler K.W., P53 function and dysfunction, Cell, 70, pp. 523-526
[6]  
Barnes D.M., Hanby A.M., Gillett C.E., Mohammed S., Hodgson S., Bobrow L.C., Et al., Abnormal expression of wild type of p53 protein in normal cells of a cancer family patient, Lancet, 340, pp. 259-263
[7]  
Hsu I.C., Metcalf R.A., Sunt T., Welsh J.A., Wang N.J., Harris C.C., Mutational hotspot in the p53 gene in human hepatocellular carcinomas, Nature, 350, pp. 427-428, (1991)
[8]  
Hosono S., Chou M.-J., Lee C.-S., Shih C., Infrequent mutation of p53 gene in hepatitis B virus positive primary hepatocellular carcinomas, Oncogene, 8, pp. 491-496, (1993)
[9]  
Challen C., Lunec J., Warren W., Collier J., Bassendine M.F., Analysis of the p53 tumor-suppressor gene in hepatocellular carcinomas from Britain, Hepatology, 16, pp. 1362-1366, (1992)
[10]  
Kress S., Jahn U.-R., Buchmann A., Bannasch P., Schwarz M., P53 mutations in human hepatocellular carcinomas from Germany, Cancer Res, 52, pp. 3220-3223, (1992)